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Background
We previously reported that male mice deficient in the
a1 subunit of the NO receptor soluble guanylate cyclase
(sGCa1
-/- mice), an important nitric oxide (NO) recep-
tor, are hypertensive [1]. The phenotype depends on the
genetic background: sGCa1
-/- mice on a 129S6 (S6)
background (sGCa1
-/-S6) but not on a C57BL/6 (B6)
background
(sGCa1
-/-B6) develop hypertension [2]. These findings
suggest that hypertension associated with sGCa1-defi-
ciency is modulated by genetic factors. We aimed to




Mean arterial blood pressure (MAP) was measured
invasively in 280 male F2 offspring from a sGCa1
-/-S6
Xs G C a1
-/-B6 intercross (sGCa1
-/-F2). All mice were
genotyped with a genome-wide panel of 150 SNP mar-
kers for linkage analysis using the Sequenom MassAr-
ray system and MAPMAKER/QTL. Renin-1c and
renin-2d genotyping was performed using gene-specific
primers. Plasma renin activity (PRA) and aldosterone
were measured in anesthetized male S6 wild-type
(WT
S6)a n ds G C a1
-/-S6 mice by radioimmunoassay and
enzyme-linked immunoassay, respectively. The renin
angiotensin system (RAS) was blocked by treating mice
with either the aldosterone receptor antagonist, Spiro-
nolactone (100 mg/kg/day, subcutaneous pellet for
7 days), or the renin inhibitor, Aliskiren (200mg/kg/
day, by gavage for 10 days).
Results
MAP in sGCa1
-/-F2 mice varied between values observed
in sGCa1
-/-S6 and sGCa1
-/-B6 mice. Linkage analysis
identified a locus on chromosome 1 with a highly signif-
icant logarithm of odds (LOD) score of 6.1. This region
is syntenic with previously identified hypertension-
related QTLs in the human and rat genome and con-
tains the gene coding for renin. Importantly, B6 mice
have one renin gene (renin-1c), and S6 mice have two
renin genes (renin-1d and renin-2). Presence of the
renin-1d and renin-2 genes correlated significantly with
elevated MAP in the F2 mice (P<0.0001). PRA was
higher in sGCa1
-/-S6 than in WT
S6 mice (0.29±0.01 vs.
0.23±0.03 µg angiotensin 1/ml/hr, respectively, P<0.05).
Similarly, plasma aldosterone levels were higher in
sGCa1
-/-S6 than in WT
S6 mice (0.47±0.03 vs 0.34±0.03
ng/ml, respectively, P<0.05). Treatment with Spironolac-
tone or Aliskiren normalized blood pressure in sGCa1
-/-
S6 (117±5 vs 146±2 mmHg, in Spironolactone and vehi-
cle-treated mice, respectively, P<0.001, and 100±7 vs
148±4 mmHg, in Aliskiren and vehicle-treated mice,
respectively, P<0.001).
Conclusion
Together, these data identify renin as a possible genetic
modifier of blood pressure in a setting of deficient NO-
cGMP signaling. Furthermore, these findings highlight
the importance of sGC in the regulation of the renin-
angiotensin system (RAS) and suggest that sGC may be
a therapeutic target in RAS-dependent hypertension.
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